BV Cyclotron VU and VU University Medical Center (VUmc) have a close partnership in research and development. VUmc occupies a relevant position among the world‘s top institutions. Their departments of Oncology and Immunology rank first in the Netherlands and 7th in Europe
In a world where only about 25% of the prescribed anticancer drugs have a therapeutic benefit, there is great room for improvement. One of the most promising fields of research on which BV Cyclotron VU and VUmc work closely together is immuno-PET, the tracking and quantification of monoclonal antibodies (mAbs). PET is a powerful innovation for improving understanding of the in vivo behavior and efficacy of mAbs. It combines the high sensitivity and resolution of a PET camera with the precision of a monoclonal antibody.
The core activities of VUmc are patient care, education, and scientific research. On average, 38,000 patients are admitted to the hospital annually, with a further 300,000 visiting the outpatient center, and 40,000 receiving emergency treatment. A staff of around 7,000 professionals and trainees are responsible for the smooth and efficient running of the Medical Center.
The scientific research carried out at VUmc is closely linked to issues that are important both for the hospital itself and for society in general. Its main focal areas are:
General: medical technology assessment (MTA), PET in drug development
Neurology: Alzheimer‘s and Parkinson‘s disease, epilepsy
Psychiatry: anxiety and depression, schizophrenia, post-traumatic stress disorder
Cardiology: myocardial ischemia, heart failure
Oncology (only main studies): lung, breast, and head and neck cancer, response monitoring (chemotherapy & radiotherapy)
The research output at VUmc translates into approximately 2,000 publications and reports per year, of which around 100 are doctoral theses.
BV Cyclotron VU and VUmc aim to expand knowledge through fundamental research and to apply this knowledge to health services via strategic and applied research.